Description
Novo Nordisk is a leading global healthcare company specializing in diabetes care, obesity, haemophilia, and growth disorders. Founded in Denmark, it develops innovative medicines and devices, combining research-driven therapies with sustainable practices. Committed to patient-centred care, Novo Nordisk aims to improve quality of life worldwide through science, accessibility, and responsibility.
Role with PROBE
With longstanding expertise in diabetes, obesity and metabolic disease that includes clinical trial design, real-world evidence generation and an approach to patient-centric care, Novo Nordisk supports the efforts of IHI PROBE to revolutionise the way OA is understood, diagnosed and treated.
